Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The European Association for Neuro-oncology (EANO) Consensus Statement on Radiation Necrosis.

Neuro-oncology·2026
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Neuro-oncology advances·2026
Same author

Brain tumor susceptibility: From genetic predisposition syndromes to extended characterization of genomic determinants.

Critical reviews in oncology/hematology·2026
Same author

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review.

Frontiers in oncology·2026
Same author

Ultrasound-Based Therapies in Primary Central Nervous System Tumors.

Cancers·2026

Related Experiment Video

Updated: Jun 2, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

Primary brain tumors in the elderly population.

Alba A Brandes1, Enrico Franceschi

  • 1Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL of Bologna, Via Altura 3, 40139, Bologna, Italy, alba.brandes@yahoo.it.

Current Treatment Options in Neurology
|April 13, 2011
PubMed
Summary

Elderly brain tumor patients present unique challenges in oncology. Further research is needed to establish optimal treatment standards for this population, particularly for glioblastoma.

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Jun 2, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Neuro-oncology

Background:

  • Elderly cancer patients, especially those with brain tumors, have distinct clinical profiles including comorbidities and reduced tolerance to standard treatments.
  • Existing data on elderly cancer patients often stem from retrospective studies with inherent selection biases, limiting applicability.
  • Ageism and concerns about toxicity contribute to underrepresentation of elderly patients in clinical trials.

Purpose of the Study:

  • To highlight the challenges in treating elderly patients with brain tumors.
  • To emphasize the need for age-specific clinical trials and treatment protocols.
  • To discuss current treatment standards and knowledge gaps for elderly glioblastoma patients.

Main Methods:

  • Review of existing literature and clinical practices for elderly cancer patients with brain tumors.
  • Analysis of treatment challenges, including comorbidities and tolerance to therapy.
  • Identification of current therapeutic approaches and areas requiring further investigation.

Main Results:

  • Clinical data from younger populations are not directly transferable to elderly patients with brain tumors.
  • Surgery followed by radiotherapy is a common approach for elderly glioblastoma patients.
  • Temozolomide is considered for patients with good clinical status, but optimal dosage and schedule remain undetermined.

Conclusions:

  • Dedicated clinical trials incorporating genetic and clinical factors are essential for elderly brain tumor patients.
  • The standard of care for elderly glioblastoma patients requires further definition, particularly regarding chemotherapy.
  • Addressing age-related factors is crucial for improving outcomes in this patient group.